Summer reflections, updates and new milestones at Zelmic

June 3, 2025

As we head into the summer months, we want to take a moment to share some exciting updates from our team at Zelmic.

New license

We’ve reached two important milestones. We’ve obtained our MIA license, where we can help clients with imports from third countries, allowing us to manage global supply chains more efficiently and compliantly. And with new capabilities in oral formulation development, we are now well-positioned to support First-in-Man studies, adding another dimension to our offering as a CDMO specialized in topical and local drug delivery.

CTR group and CTC

Since July 2024, Zelmic is proud to be part of the CTR Group together with its subsidiaries. With CTC, we form a strong and integrated clinical development capacity for non-sterile First-in-Human trials, enabling seamless transitions from early formulation to clinical execution.

IVPT and PD studies

Looking ahead, we remain focused on advancing dermatology and local drug delivery. Alongside our IVPT work, we are also developing new pharmacodynamic models to better support early efficacy evaluation.

To our partners

To all our clients, collaborators, and colleagues – thank you for being part of our journey. We wish you a relaxing and well-deserved summer. We’re looking forward to continuing the conversation and innovation after the break.

Warm summer wishes from all of us at Zelmic

See all news